CELL INTELLIGENCE · 肿瘤细胞治疗研究

没有 BCMA？没问题：靶向 CD70 的 CAR-NK 细胞在高危骨髓瘤中展现前景

No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.

靶向 CD70 的 CAR-NK 细胞克服 BCMA 下调并改善高危多发性骨髓瘤模型中的生存

CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.

通过靶向 CD70 的同种异体 CAR-NKT 细胞多模式靶向转移性肾细胞癌

Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells.

将去甲基化药物与现货型 CD70 靶向嵌合抗原受体工程化自然杀伤 T 细胞协同用于治疗急性髓系白血病

Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of a

CD28 共刺激经 LCK/CD3ζ/ZAP70 信号轴增强 NK 细胞中的 CAR 信号传导

CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis.

CD70 是 EMT 相关 EGFR 酪氨酸激酶抑制剂耐药中上调的治疗靶点

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.

MK-5890 的临床前特征及药效学标志物的临床转化：一种用于癌症免疫治疗的人 CD27 激活抗体

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherap

MK-5890 是一种新型 CD27 激动剂抗体，具有在癌症免疫治疗中补充 PD-1 检查点抑制活性的潜力，目前正在进行临床评估。

非病毒 TcBuster 转座子工程化 CD70-CAR NK 细胞治疗骨肉瘤

Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma.

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.

何时应怀疑 EB 病毒相关淋巴增殖性疾病中存在先天性免疫缺陷

When to suspect inborn errors of immunity in Epstein-Barr virus-related lymphoproliferative disorders.

对于 EBV 相关淋巴增殖性疾病，建议进行 IEIs 的早期筛查，因为不同形式的 IEIs 具有特定的预后和治疗意义。